Biotech IPOs; don't let the numbers deceive
Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital — […]
Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital — […]
Biotech IPOs; don’t let the numbers deceive Take the biotechnology industry, which in 2003 raised $16.7 billion in capital —
Purple Haze The prospects of a medicinal version of cannabis being produced have never been better but manufacturers are still
Financial Snapshot For December 2003 Bulls Charge Ahead
What’s Next for Pharma? Experts from the Tufts Center for the Study of Drug Development discuss the outlook for R&D,
What’s Next for Pharma? Experts from the Tufts Center for the Study of Drug Development discuss the outlook for R&D,
India: Big Pharma’s New Promised Land? For years, software companies have known that they can slash costs by hiring eager,
India: Big Pharma’s New Promised Land? For years, software companies have known that they can slash costs by hiring eager,
Genetically engineered Glofish spark controversy The nation’s first genetically engineered pet glows in the dark and has been lighting up
Genetically engineered Glofish spark controversy Read Post »
Feeling Lucky? Counterfeiters have moved beyond bogus currency and fake designer handbags into the lucrative world of prescription drugs, setting
Get new actionable insights and updates from BiotechBlog